Tech Company Financing Transactions
Oncobiologics Funding Round
Oncobiologics, based in Cranbury, scored $31 million from Perceptive Advisors, Cormorant Asset Management and Longwood Fund.
Transaction Overview
Company Name
Announced On
7/27/2015
Transaction Type
Venture Equity
Amount
$31,000,000
Round
Undisclosed
Investors
Perceptive Advisors (Lead Investor) (Joseph Edelman)
Proceeds Purpose
Proceeds will be used to support continued development and expansion of the company's proprietary BioSymphony biosimilar platform and advancement of its preclinical and clinical programs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
7 Clarke Dr.
Cranbury, NJ 08512
USA
Cranbury, NJ 08512
USA
Phone
Website
Email Address
Overview
Oncobiologics is committed to advancing biotherapeutics to treat serious diseases, including cancer and immune disorders through the development of both novel molecules using the TRIDENT� platform and biosimilar monocolonal antibodies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Lawrence Kenyon
Chief Medical Officer
Kenneth Bahrt
VP - Bus. Development
Stephen McAndrew
VP - Manufacturing
Chuck Hart
VP - Regulatory Affairs
Myrna Thomas
Browse more venture capital transactions:
Prev: 7/27/2015: Perch Interactive venture capital transaction
Next: 7/27/2015: eFFECTOR Therapeutics venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs